Abstract

Prothrombin time (PT) is the leading test for monitoring oral anticoagulation therapy (OAT). We sought to determine INR taking into account only active coagulation factors FII, FVII and FX without inhibition in patient plasmas and calibrator kits.We measured PT using a combined thromboplastin reagent. The calculation was based on a new PT method, which measures active coagulation factors (F II, F VII, FX) and corrects the errors caused by inactive coagulation factors.On this basis, an INR result with and without inhibition for individual patient samples was also calculated and applied to 200 plasma samples obtained from OAT patients. Conspicuous variation in inhibition between the four calibration kits was noted. The kinetics of this inhibition was closest to a noncompetitive pattern.The need of correction for INRs of single patients increases with higher INRs. At the same level of patient INRs the coagulation inhibiton varies markedly.It has been known that different thromboplastin reagents possess variable sensitivities, but this may depend on sensitivity in inactive coagulation factors. PT methods today measure the sum of active coagulation factors and inhibition of inactive coagulation factors. ISI calibrators contain variable amounts of inactive coagulation factors, which renders harmonisation of INR results.Application of the Acf-PT (INRAcf) presented in this work develops the PT methodology to measure the true coagulation activity in vivo for patient warfarin therapy without inhibition. INRInh can evidently also be used for the diagnostics and follow-up of certain liver diseases.

Highlights

  • Oral anticoagulation therapy (OAT) is - globally - one of the most widely used medications

  • All thromboplastins should be calibrated in terms of the International Sensitivity Index (ISI) and the prothrombin time test (PT) results given in INR (International Normalized Ratio) units [2]

  • Standardization should be performed by comparing the results from test thromboplastin with those given by a reference thromboplastin calibrated in accordance with the method recommended by the WHO Expert Committee on Biological Standardization [2,3]

Read more

Summary

Introduction

Oral anticoagulation therapy (OAT) is - globally - one of the most widely used medications. The prothrombin time test (PT) was introduced by Quick more than 70 years ago. It has served as a basis for OAT monitoring from the beginning of this therapy. According to a recent review the problem with this test, has been the poor comparability of results obtained in different laboratories [1]. Standardization should be performed by comparing the results from test thromboplastin with those given by a reference thromboplastin calibrated in accordance with the method recommended by the WHO Expert Committee on Biological Standardization [2,3].

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.